Nanjing Hicin Pharmaceutical Co., Ltd. (SHE:300584)

SHE:300584 Income Statement

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 31, 2025	Dec 31, 2024	Dec 31, 2023	Jan 1, 2023	Jan 1, 2022	Dec 31, 2020
Operating Revenue	540.2	502.11	515.98	522.73	570.8	704.09
Other Revenue	2.25	2.25	1.85	3.73	7.52	2.21
Revenue	542.45	504.36	517.83	526.47	578.32	706.3
Revenue Growth (YoY)	7.37%	-2.60%	-1.64%	-8.97%	-18.12%	-23.61%
Cost of Revenue	94.23	93.07	101.28	133.79	109.93	174.61
Gross Profit	448.21	411.29	416.56	392.68	468.39	531.69
Selling, General & Admin	347.69	309.65	313.51	325.99	403.48	422.13
Research & Development	39.18	40.28	46.63	18.22	21.7	31.88
Other Operating Expenses	10.31	9.8	8.81	9.77	12.48	12.38
Operating Expenses	395.1	358.89	370.61	358.05	438.98	466.09
Operating Income	53.11	52.4	45.94	34.63	29.41	65.59
Interest Expense	-8.69	-8.98	-8.27	-7.25	-7.5	-7.01
Interest & Investment Income	0.09	0.12	0.96	1.02	0.78	0.51
Currency Exchange Gain (Loss)	-0.01	-0.01	0.02	0.01	-0.06	0.01
Other Non Operating Income (Expenses)	-0.15	-0.23	-0.09	-0.54	-0.02	-0.03
EBT Excluding Unusual Items	44.37	43.3	38.56	27.86	22.61	59.07
Gain (Loss) on Sale of Investments	-0.01	-	0.04	0.93	306.31	0.08
Gain (Loss) on Sale of Assets	-0.18	-	-0.79	-0.95	-0.02	-0.07
Asset Writedown	-2.9	-2.09	-0.04	-0.92	-0.29	-0.92
Other Unusual Items	-0.17	-0.19	-0.08	1.86	1.83	3.19
Pretax Income	41.11	41.03	37.69	28.78	330.45	61.35
Income Tax Expense	-0.66	0.87	1.37	-3.35	45.61	6.82
Earnings From Continuing Operations	41.77	40.16	36.32	32.12	284.83	54.53
Minority Interest in Earnings	0.13	0.05	-	0.32	1.05	0.7
Net Income	41.9	40.22	36.32	32.45	285.88	55.23
Net Income to Common	41.9	40.22	36.32	32.45	285.88	55.23
Net Income Growth	11.85%	10.75%	11.92%	-88.65%	417.61%	-43.21%
Shares Outstanding (Basic)	120	120	120	120	120	120
Shares Outstanding (Diluted)	120	120	120	120	120	120
Shares Change (YoY)	-0.01%	0.01%	0.01%	0.00%	0.01%	-0.01%
EPS (Basic)	0.35	0.34	0.30	0.27	2.38	0.46
EPS (Diluted)	0.35	0.34	0.30	0.27	2.38	0.46
EPS Growth	11.85%	10.74%	11.91%	-88.65%	417.55%	-43.21%
Free Cash Flow	22.67	-17.98	-173.29	-224.76	-34.47	-46.71
Free Cash Flow Per Share	0.19	-0.15	-1.44	-1.87	-0.29	-0.39
Dividend Per Share	0.100	0.100	0.050	-	0.250	0.125
Dividend Growth	100.00%	100.00%	-	-	100.00%	-50.00%
Gross Margin	82.63%	81.55%	80.44%	74.59%	80.99%	75.28%
Operating Margin	9.79%	10.39%	8.87%	6.58%	5.09%	9.29%
Profit Margin	7.72%	7.97%	7.01%	6.16%	49.43%	7.82%
Free Cash Flow Margin	4.18%	-3.56%	-33.46%	-42.69%	-5.96%	-6.61%
EBITDA	105.78	105.25	99.49	82.69	66.41	97.14
EBITDA Margin	19.50%	20.87%	19.21%	15.71%	11.48%	13.75%
D&A For EBITDA	52.67	52.85	53.55	48.07	37	31.55
EBIT	53.11	52.4	45.94	34.63	29.41	65.59
EBIT Margin	9.79%	10.39%	8.87%	6.58%	5.09%	9.29%
Effective Tax Rate	-	2.11%	3.65%	-	13.80%	11.12%
Revenue as Reported	542.45	504.36	517.83	526.47	578.32	706.3

Source: S&P Global Market Intelligence. Standard template. Financial Sources.